13.14
1.22 (10.23%)
| Previous Close | 11.92 |
| Open | 11.84 |
| Volume | 3,707,305 |
| Avg. Volume (3M) | 4,197,458 |
| Market Cap | 1,743,526,784 |
| Price / Book | 12.19 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Diluted EPS (TTM) | -9.25 |
| Total Debt/Equity (MRQ) | 13.68% |
| Current Ratio (MRQ) | 2.33 |
| Operating Cash Flow (TTM) | -644.94 M |
| Levered Free Cash Flow (TTM) | -394.10 M |
| Return on Assets (TTM) | -129.99% |
| Return on Equity (TTM) | -316.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Biohaven Ltd. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -3.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 11.96% |
| % Held by Institutions | 90.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Suvretta Capital Management, Llc | 30 Sep 2025 | 5,620,271 |
| Bellevue Group Ag | 30 Sep 2025 | 2,802,853 |
| Infinitum Asset Management, Llc | 30 Sep 2025 | 1,700,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 22.00 (RBC Capital, 67.43%) | Buy |
| Median | 15.00 (14.16%) | |
| Low | 9.00 (Bernstein, -31.51%) | Hold |
| Average | 14.89 (13.32%) | |
| Total | 6 Buy, 3 Hold | |
| Avg. Price @ Call | 9.71 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 21 Jan 2026 | 22.00 (67.43%) | Buy | 13.14 |
| 06 Nov 2025 | 9.00 (-31.51%) | Hold | 8.53 | |
| Morgan Stanley | 06 Jan 2026 | 21.00 (59.82%) | Buy | 9.62 |
| 18 Nov 2025 | 26.00 (97.87%) | Buy | 9.45 | |
| HC Wainwright & Co. | 26 Dec 2025 | 11.00 (-16.29%) | Hold | 11.15 |
| 03 Dec 2025 | 11.00 (-16.29%) | Hold | 9.12 | |
| UBS | 26 Nov 2025 | 11.00 (-16.29%) | Hold | 9.48 |
| JP Morgan | 20 Nov 2025 | 15.00 (14.16%) | Buy | 9.63 |
| BTIG | 18 Nov 2025 | 16.00 (21.77%) | Buy | 9.45 |
| 06 Nov 2025 | 16.00 (21.77%) | Buy | 8.53 | |
| Citigroup | 13 Nov 2025 | 14.00 (6.54%) | Buy | 8.08 |
| Bernstein | 06 Nov 2025 | 9.00 (-31.51%) | Hold | 8.53 |
| TD Cowen | 05 Nov 2025 | 15.00 (14.16%) | Buy | 8.34 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |